Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Subsidiary Centocor Extends Collaboration With New Zealand's Living Cell Technologies For Encapsulation Technology

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Johnson & Johnson subsidiary Centocor has extended its two-year research collaboration with New Zealand-based Living Cell Technologies, and signed on for an exclusive two-year option to license globally LCT's encapsulation technology for human cell lines
Advertisement

Related Content

New Zealand's Living Cell Technologies Cleared For Phase II Diabetes Trials As Pig Herd Becomes More Famous
New Zealand's Living Cell Technologies Cleared For Phase II Diabetes Trials As Pig Herd Becomes More Famous
Stranded Pigs Rescued By NZ Biotech, Helicon SFDA Approval For Skin Regeneration Device, Arana Ramps Up R&D - Australia/New Zealand Roundup
Stranded Pigs Rescued By NZ Biotech, Helicon SFDA Approval For Skin Regeneration Device, Arana Ramps Up R&D - Australia/New Zealand Roundup
Advertisement
UsernamePublicRestriction

Register

SC070658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel